Continue Reading
Full article on MarketWatch
Moderna got the FDA to change its mind and review its flu vaccine after some concessions
Market Intelligence Analysis
AI-Powered
Why This Matters
Moderna's stock surged after the FDA agreed to review its flu-vaccine candidate, reversing a previous decision, following concessions made by the company.
Market Impact
Market impact analysis based on bullish sentiment with 90% confidence.
Sentiment
Bullish
AI Confidence
90%
Time Horizon
Short Term
Article Context
Note: This is a brief excerpt for context. Click below to read the full article on the original source.
Moderna’s stock was surging after the FDA said it would review the biotech’s flu-vaccine candidate, a week after it had refused to do so.
Original article published by
MarketWatch
on February 18, 2026.
Analysis and insights provided by AnalystMarkets AI.
Analysis and insights provided by AnalystMarkets AI.